Where does Modalis Therapeutics Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Modalis Therapeutics Corporation ranks #48,818 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Modalis Therapeutics Corporation hold?

Modalis Therapeutics Corporation holds 5 US utility patents granted between 2022 and 2024, spanning 4 technology areas.

What is Modalis Therapeutics Corporation's Innovation Score?

Modalis Therapeutics Corporation has an Innovation Score of 43.1 out of 100 (top 29% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Modalis Therapeutics Corporation's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Modalis Therapeutics Corporation.

What does claim depth mean for Modalis Therapeutics Corporation's patents?

Modalis Therapeutics Corporation's patents average 16.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Modalis Therapeutics Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Modalis Therapeutics Corporation

Q: What technology areas does Modalis Therapeutics Corporation focus on?

Modalis Therapeutics Corporation's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 5 patents, ranking #1,801 of 4,144 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2022–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Modalis ranks #48,818 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.

#48,818
of 49,997 US assignees by volume: Top 29%
by Innovation Score (43.1/100): 16.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R48818 · Foreign Corporation #48,818 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
BOTTOM-DECILE #48,818/49,997
PHOTO-FINISH Mobeewave
CPC-NARROW C12N · 4 areas
INNOV-PAR 43.1/100
CLAIMS-RICH 16.4 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2022–2024 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Mobeewave, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Modalis’s 43.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (14%) Velocity 20.0 pts (46%) Breadth 7.1 pts (16%) Claim depth 9.8 pts (23%)

Qualcomm Incorporated · highest

85
Jeju National… · near

43
Modalis Therapeutics · this assignee

43
Solvay USA · near

43
Spirox · near

43
Xiamen Water Nymph… · near

43
3D Lighting… · lowest

7

What this shows Modalis's Innovation Score is 43.1/100 (top 29% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Modalis?

Each dot is one of Modalis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Modalis’s own 16.4 claims/patent is at or below the 17.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Modalis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Modalis's grants concentrate

Modalis Therapeutics Corporation is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2023. By volume, Modalis sits between Mobeewave, Inc. and Modula S.P.A. CON Socio Unico.

Modalis's three-year grant acceleration

Modalis Therapeutics Corporation shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Mobeewave

5
Mobile Communicat…

5
Mobileconn Techno…

5
Mobileodt

5
Modine

5
Modiv Media

5
Modrendesign PTY

5
Modula S P A CON…

5
Modalis Therapeut… ◀

5

What this shows Modalis holds 5 patents at rank #48,672, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Modalis

By rank, the assignees closest to #48,672 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Modalis's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Modalis, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Modalis ranks #1,801 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (43 here).

Spirox, Inc. 43 Solvay USA Inc. 43 Jeju National University Industry-Academic Cooperation Foundation 43 Xiamen Water Nymph Sanitary Technology Co., Ltd. 43

Modalis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 29% higher than 71% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Modalis Therapeutics Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	3	60.0%
2023	1	20.0%
2024	1	20.0%

Which technologies does Modalis Therapeutics Corporation patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C07K - Peptides 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 2

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Modalis Therapeutics Corporation's patent record in context - here's where to go next.

Modalis Therapeutics Corporation's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #48,818 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Modalis Therapeutics Corporation against Mobeewave, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.